ERBB2 and breast carcinoma: As indicated in Figure 2A,B SERCA-A1-3 expression levels were elevated and altered in patients with breast cancer, where further analysis (Figure 3A–C) showed that SERCA-A1, A2, and A3 had a differential expression profile in breast cancer subclasses, including luminal, HER2-positive, and TNBC.